BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 36049097)

  • 1. Using Molecular Subtyping of Pancreatic Ductal Adenocarcinoma for Multimodal Treatment Selection in Resectable Disease.
    Dima SO; Dumitraşcu T; Popescu I; Duda DG
    Chirurgia (Bucur); 2022 Jun; 117(4):407-414. PubMed ID: 36049097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of Surgery and Perioperative Therapy in Older Patients with Resectable Pancreatic Ductal Adenocarcinoma.
    Xie H; Liu J; Yin J; Ogden JR; Mahipal A; McWilliams RR; Truty MJ; Bekaii-Saab TS; Petersen GM; Jatoi A; Hubbard JM; Ma WW
    Oncologist; 2020 Nov; 25(11):e1681-e1690. PubMed ID: 32663355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A single center experience in resectable pancreatic ductal adenocarcinoma : the limitations of the surgery-first approach. Critical review of the literature and proposals for practice update.
    Dumont R; Puleo F; Collignon J; Meurisse N; Chavez M; Seidel L; Gast P; Polus M; Loly C; Delvenne P; Meunier P; Hustinx R; Deroover A; Detry O; Louis E; Martinive P; Van Daele D
    Acta Gastroenterol Belg; 2017; 80(4):451-461. PubMed ID: 29560639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New challenges in perioperative management of pancreatic cancer.
    Puleo F; Maréchal R; Demetter P; Bali MA; Calomme A; Closset J; Bachet JB; Deviere J; Van Laethem JL
    World J Gastroenterol; 2015 Feb; 21(8):2281-93. PubMed ID: 25741134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after curative intent surgical resection.
    Kim NH; Kim HJ
    Hepatobiliary Pancreat Dis Int; 2018 Oct; 17(5):450-455. PubMed ID: 30237091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The past, present, and future status of multimodality treatment for resectable/borderline resectable pancreatic ductal adenocarcinoma.
    Sakaguchi T; Satoi S; Yamamoto T; Yamaki S; Sekimoto M
    Surg Today; 2020 Apr; 50(4):335-343. PubMed ID: 31993761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Borderline resectable pancreatic cancer.
    Hackert T; Ulrich A; Büchler MW
    Cancer Lett; 2016 Jun; 375(2):231-237. PubMed ID: 26970276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical challenges associated with utility of neoadjuvant treatment in patients with pancreatic ductal adenocarcinoma.
    Gray S; de Liguori Carino N; Radhakrishna G; Lamarca A; Hubner RA; Valle JW; McNamara MG
    Eur J Surg Oncol; 2022 Jun; 48(6):1198-1208. PubMed ID: 35264307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival benefit of neoadjuvant therapy in patients with non-metastatic pancreatic ductal adenocarcinoma: A propensity matching and intention-to-treat analysis.
    Sugimoto M; Takahashi N; Farnell MB; Smyrk TC; Truty MJ; Nagorney DM; Smoot RL; Chari ST; Carter RE; Kendrick ML
    J Surg Oncol; 2019 Nov; 120(6):976-984. PubMed ID: 31452208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant therapy for localized pancreatic ductal adenocarcinoma.
    Brown ZJ; Shannon AH; Cloyd JM
    Minerva Surg; 2024 Jun; 79(3):315-325. PubMed ID: 38385797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of radiotherapy in multimodal treatment of pancreatic carcinoma.
    Brunner TB; Scott-Brown M
    Radiat Oncol; 2010 Jul; 5():64. PubMed ID: 20615227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response to Neoadjuvant Therapy and Prognosis in Patients with Resectable Pancreatic Cancer: A Propensity Score Matching Analysis.
    Yoon MS; Lee HS; Kang CM; Lee WJ; Keum J; Sung MJ; Kim SS; Park MS; Jo JH; Chung MJ; Park JY; Park SW; Song SY; Hwang HK; Bang S
    Gut Liver; 2022 Jan; 16(1):118-128. PubMed ID: 34140428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette study.
    Heinrich S; Besselink M; Moehler M; van Laethem JL; Ducreux M; Grimminger P; Mittler J; Lang H; Lutz MP; Lesurtel M;
    BMC Cancer; 2019 Jul; 19(1):675. PubMed ID: 31288786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative independent prognostic factors in patients with borderline resectable pancreatic ductal adenocarcinoma following curative resection: the neutrophil-lymphocyte and platelet-lymphocyte ratios.
    Asari S; Matsumoto I; Toyama H; Shinzeki M; Goto T; Ishida J; Ajiki T; Fukumoto T; Ku Y
    Surg Today; 2016 May; 46(5):583-92. PubMed ID: 26108488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proposed preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after surgical resection: A multi-center retrospective study.
    Matsumoto I; Murakami Y; Shinzeki M; Asari S; Goto T; Tani M; Motoi F; Uemura K; Sho M; Satoi S; Honda G; Yamaue H; Unno M; Akahori T; Kwon AH; Kurata M; Ajiki T; Fukumoto T; Ku Y
    Pancreatology; 2015; 15(6):674-80. PubMed ID: 26467797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative evaluation of pancreatic ductal adenocarcinoma with synchronous liver metastasis: Diagnosis and assessment of unresectability.
    Shi HJ; Jin C; Fu DL
    World J Gastroenterol; 2016 Dec; 22(45):10024-10037. PubMed ID: 28018110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant treatment of surgically resectable pancreatic ductal adenocarcinoma.
    Tesfaye AA; Philip PA
    Clin Adv Hematol Oncol; 2019 Jan; 17(1):54-63. PubMed ID: 30843899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and Validation of a Biomarker Signature in Patients With Resectable Pancreatic Cancer via Genome-Wide Screening for Functional Genetic Variants.
    Dimitrakopoulos C; Vrugt B; Flury R; Schraml P; Knippschild U; Wild P; Hoerstrup S; Henne-Bruns D; Wuerl P; Graf R; Breitenstein S; Bond G; Beerenwinkel N; Grochola LF
    JAMA Surg; 2019 Jun; 154(6):e190484. PubMed ID: 30942874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update on the management of pancreatic cancer: surgery is not enough.
    Ansari D; Gustafsson A; Andersson R
    World J Gastroenterol; 2015 Mar; 21(11):3157-65. PubMed ID: 25805920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer outcomes are independent of preoperative CA 19-9 in anatomically resectable pancreatic ductal adenocarcinoma: A retrospective cohort analysis.
    Kim JK; DePeralta DK; Ogami T; Denbo JW; Pimiento J; Hodul PJ; Malafa MP; Kim DW; Fleming JB; Powers BD
    J Surg Oncol; 2020 Nov; 122(6):1074-1083. PubMed ID: 32673436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.